Grufity logoGrufity logo
StocksFundsSearch Filings

Vertex Pharmaceuticals Inc Stock Research

VRTX

329.99USD-2.64(-0.79%)Market Closed

Market Summary

USD329.99-2.64
Market Closed
-0.79%

VRTX Alerts

VRTX Stock Price

VRTX RSI Chart

VRTX Valuation

Market Cap

85.0B

Price/Earnings (Trailing)

26.07

Price/Sales (Trailing)

9.23

EV/EBITDA

17.74

Price/Free Cashflow

21.84

VRTX Price/Sales (Trailing)

VRTX Profitability

EBT Margin

47.39%

Return on Equity

23.88%

Return on Assets

18.3%

Free Cashflow Yield

4.58%

VRTX Fundamentals

VRTX Revenue

Revenue (TTM)

9.2B

Revenue Y/Y

13.22%

Revenue Q/Q

3.13%

VRTX Earnings

Earnings (TTM)

3.3B

Earnings Y/Y

-8.17%

Earnings Q/Q

-14.54%

Price Action

52 Week Range

243.17354.46
(Low)(High)

Last 7 days

-3.4%

Last 30 days

2.1%

Last 90 days

14.8%

Trailing 12 Months

22.4%

VRTX Financial Health

Current Ratio

4.83

VRTX Investor Care

Shares Dilution (1Y)

0.76%

Diluted EPS (TTM)

12.55

Peers (Alternatives to Vertex Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
322.8B
1.6B
-3.71% 80.48%
-168.39
207.32
77.54% 1.62%
285.4B
56.7B
-14.98% -6.85%
24.12
4.92
0.03% -39.22%
87.6B
12.4B
-6.81% 6.09%
20.2
7.2
-25.07% -47.28%
85.0B
9.2B
2.07% 22.38%
26.07
9.23
15.86% 32.99%
23.4B
1.0B
-4.69% 49.89%
-21.96
22.55
22.88% -19.27%
11.8B
975.7M
3.71% 78.87%
-10.59
12.11
27.41% -212.78%
9.7B
2.0B
-8.21% -7.77%
13.31
4.89
12.05% 52.86%
MID-CAP
5.2B
504.0K
-7.29% 316.43%
-16.55
2.5K
-66.53% -27.52%
3.5B
363.3M
17.72% 8.70%
-4.94
9.63
3.39% -55.81%
3.5B
204.6M
17.81% 4.32%
-6
17.05
-7.52% 10.65%
2.2B
18.9M
-10.74% -34.21%
-3.03
118.36
- -16.17%
SMALL-CAP
3.5B
-
0.59% -4.18%
-8.22
37.46
34.30% -67.22%
1.2B
256.5M
-28.21% 63.82%
12.26
4.75
66.85% 120.61%
315.4M
165.3M
-25.22% 48.69%
-3.45
1.91
130.70% 57.97%
41.8M
881.7K
29.00% 3203.36%
-0.83
19.11
-77.61% -29.84%

Financials for Vertex Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue3.1%9,2088,9318,7018,3507,948
  S&GA Expenses2.7%971945933884863
  R&D Expenses-3,198----
Costs and Expenses11.7%5,1634,6234,5494,2715,012
EBITDA5.2%4,3264,1124,0122,936-
EBITDA Margin2.5%0.48*0.47*0.48*0.37*-
Earnings Before Taxes-1.5%4,1694,2324,0273,9332,864
EBT Margin2.4%0.47*0.46*0.47*0.36*-
Interest Expenses6.0%-54.80-58.30-59.80-60.70-
Net Income-1.9%3,2603,3223,2733,1952,451
Net Income Margin-1.1%0.37*0.38*0.38*0.31*-
Free Cahsflow2.9%3,9253,8143,7872,451-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets4.5%18,97418,15116,70615,58214,256
  Current Assets-2.0%12,96613,23512,27111,50410,361
    Cash Equivalents-11.6%9,29010,5049,1728,7027,600
  Inventory16.2%535461388368339
  Goodwill-1.1%1,0881,10086.001,0021,002
Liabilities7.2%4,5424,2383,6773,6493,349
  Current Liabilities10.4%3,0262,7422,6092,5562,180
Shareholder's Equity3.7%14,43213,91313,03011,93410,907
  Retained Earnings10.7%7,2236,5235,7044,7733,963
  Additional Paid-In Capital-2.3%7,2207,3877,2267,1006,930
Shares Outstanding0.2%258257257256256
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-1.4%4,0744,1304,0474,0182,679
  Share Based Compensation-1.6%483491498466457
Cashflow From Investing-555.2%-2,103-321-630-299-317
Cashflow From Financing-294.4%-267-67.70-444-1,040-1,054
  Buy BacksInfinity%1330.003681,0101,010

Risks for VRTX

What is the probability of a big loss on VRTX?

25.8%


Probability that Vertex Pharmaceuticals stock will be more than 20% underwater in next one year

6.5%


Probability that Vertex Pharmaceuticals stock will be more than 30% underwater in next one year.

0%


Probability that Vertex Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VRTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Vertex Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for VRTX

Cumulative Returns on VRTX

15.5%


10-Year Cumulative Returns

20.3%


7-Year Cumulative Returns

15.9%


5-Year Cumulative Returns

7.4%


3-Year Cumulative Returns

What are the long-term rolling returns for VRTX?

FIve years rolling returns for Vertex Pharmaceuticals.

Annualized Returns

Which funds bought or sold VRTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-24
Old North State Trust, LLC
unchanged
-
3,000
32,000
0.02%
2023-05-23
Toroso Investments, LLC
added
43.09
3,909,000
10,878,000
0.19%
2023-05-23
Seaport Global Advisors, LLC
reduced
-34.06
-138,205
354,454
1.12%
2023-05-23
Brookfield Corp /ON/
new
-
366,426
366,426
-%
2023-05-23
3Chopt Investment Partners, LLC
new
-
1,920,350
1,920,350
1.02%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-5.28
34,587,100
1,068,030,000
0.35%
2023-05-22
PUTNAM INVESTMENTS LLC
reduced
-11.22
-1,213,060
37,475,400
0.06%
2023-05-22
Raleigh Capital Management Inc.
new
-
5,986
5,986
-%
2023-05-22
Arete Wealth Advisors, LLC
new
-
236,000
236,000
0.02%
2023-05-22
FDx Advisors, Inc.
unchanged
-
-
2,075,000
0.09%

1–10 of 43

Latest Funds Activity

Are funds buying VRTX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own VRTX
No. of Funds

Vertex Pharmaceuticals News

Nasdaq
Wall Street Thinks This Stock Will Only Rise 12%: Here's Why It ....
Nasdaq,
23 hours ago
The Motley Fool
The Motley Fool
The Motley Fool
The Motley Fool Australia
London South East

Schedule 13G FIlings of Vertex Pharmaceuticals

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital world investors
5.0%
12,939,319
SC 13G
Feb 09, 2023
vanguard group inc
8.39%
21,546,903
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G
Jan 24, 2023
blackrock inc.
9.4%
24,241,437
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
2.1%
5,421,291
SC 13G/A
Feb 10, 2022
vanguard group inc
7.93%
20,155,842
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 01, 2022
blackrock inc.
9.4%
23,944,931
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
7.5%
19,626,208
SC 13G/A
Feb 10, 2021
vanguard group inc
7.86%
20,433,050
SC 13G/A

VRTX Fair Value

Recent SEC filings of Vertex Pharmaceuticals

View All Filings
Date Filed Form Type Document
May 18, 2023
8-K
Current Report
May 09, 2023
4
Insider Trading
May 09, 2023
4
Insider Trading
May 08, 2023
144
Notice of Insider Sale Intent
May 08, 2023
144
Notice of Insider Sale Intent
May 05, 2023
144
Notice of Insider Sale Intent
May 05, 2023
144
Notice of Insider Sale Intent
May 04, 2023
4
Insider Trading
May 04, 2023
4
Insider Trading
May 03, 2023
4
Insider Trading

Latest Insider Trading transactions for VRTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-08
Sanna Bastiano
sold
-997,500
350
-2,850
evp, cell & genetic therapies
2023-05-08
LEIDEN JEFFREY M
sold
-392,625
349
-1,125
executive chairman
2023-05-05
LEIDEN JEFFREY M
sold
-307,262
349
-879
executive chairman
2023-05-05
Sanna Bastiano
sold
-147,713
350
-422
evp, cell & genetic therapies
2023-05-03
Sanna Bastiano
sold
-975,418
350
-2,781
evp, cell & genetic therapies
2023-05-03
LEIDEN JEFFREY M
sold
-1,578,300
350
-4,508
executive chairman
2023-05-02
Sanna Bastiano
sold
-568,768
350
-1,622
evp, cell & genetic therapies
2023-05-02
Bhatia Sangeeta N.
sold
-202,004
348
-580
-
2023-05-02
LEIDEN JEFFREY M
sold
-2,256,760
349
-6,450
executive chairman
2023-05-01
MCKENZIE DIANA
acquired
-
-
1,168
-

1–10 of 50

Reshma Kewalramani
3900
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

VRTX Income Statement

2023-03-31
Condensed Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues:  
Product revenues, net$ 2,374.8$ 2,097.5
Costs and expenses:  
Cost of sales266.9245.8
Research and development expenses742.6601.1
Acquired in-process research and development expenses347.12.0
Selling, general and administrative expenses241.1215.2
Change in fair value of contingent consideration(1.9)(7.5)
Total costs and expenses1,595.81,056.6
Income from operations779.01,040.9
Interest income122.61.6
Interest expense(11.4)(14.9)
Other income (expense), net1.3(72.8)
Income before provision for income taxes891.5954.8
Provision for income taxes191.7192.7
Net income$ 699.8$ 762.1
Net income per common share:  
Basic (in dollars per share)$ 2.72$ 2.99
Diluted (in dollars per share)$ 2.69$ 2.96
Shares used in per share calculations:  
Basic (in shares)257.4255.1
Diluted (in shares)260.3257.9

VRTX Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 9,289.9$ 10,504.0
Marketable securities1,124.2274.5
Accounts receivable, net1,547.81,442.2
Inventories535.1460.6
Prepaid expenses and other current assets468.7553.5
Total current assets12,965.713,234.8
Property and equipment, net1,111.71,108.4
Goodwill1,088.01,088.0
Intangible assets603.6603.6
Deferred tax assets1,359.91,246.9
Operating lease assets336.3347.4
Long-term marketable securities1,081.5112.2
Other assets427.5409.6
Total assets18,974.218,150.9
Current liabilities:  
Accounts payable323.2303.9
Accrued expenses2,326.02,126.7
Other current liabilities377.0311.5
Total current liabilities3,026.22,742.1
Long-term finance lease liabilities417.6430.8
Long-term operating lease liabilities371.6379.5
Other long-term liabilities726.5685.8
Total liabilities4,541.94,238.2
Commitments and contingencies0.00.0
Shareholders’ equity:  
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding0.00.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 257,509,761 and 257,011,628 shares issued and outstanding, respectively2.62.6
Additional paid-in capital7,220.27,386.5
Accumulated other comprehensive (loss) income(13.1)0.8
Retained earnings7,222.66,522.8
Total shareholders’ equity14,432.313,912.7
Total liabilities and shareholders’ equity$ 18,974.2$ 18,150.9